Tag Archives: review

FDA review of troubled drug could hobble AMAG in proxy fight with activist investor

Amid a proxy fight with an activist investor in the ranks, AMAG has a message for its shareholders: Don’t worry, we’ve got a plan. But with the FDA potentially pulling a hoped-for prospect off the market, mark another notch in the activists’ belt. On Oct. 29, an FDA advisory committee will review AMAG’s marketing application… Read More »

Patent court to review Alexion’s Soliris patents on Amgen challenge

(Reuters) – The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith The move deals… Read More »

Price Transparency in Health Care Is Coming to the US — But Will It Matter? – Harvard Business Review

Executive Summary President Trump has instructed federal agencies to use their authority (established in part under provisions of the Affordable Care Act, which the administration regards as unconstitutional) to develop federal rules requiring disclosure of hospital prices in consumer-friendly, electronic form. This would include not just the list prices that hospitals purport to charge but… Read More »